← All trials
NCT05324774
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 28, 2022
- Primary completion
- Sep 30, 2023
- Completion date
- Jul 30, 2024
- First posted
- Apr 12, 2022
- Last posted
- Apr 12, 2022
- Enrollment
- 346
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- MabwellLead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.